Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.72 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.72 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.72 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | IGF2R | P11717 | 6/20 | 0.45 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685515 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL16556532 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL10031527 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL14169191 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL18680155 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL13917320 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL416471 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL18685517 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL22068039 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4SLC2A1IGF2R | |
| SCHEMBL12984161 | 0.95 | LGALS3 (0.67) | LGALS3LGALS8LGALS4SLC2A1IGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021056-A1 | Methods and Systems for Inducing Immunologic Tolerance to Non-Self Antigens | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021056-A1 | Methods and Systems for Inducing Immunologic Tolerance to Non-Self Antigens | CD47, CD74, HLA-C | LGALS3 26/4885LGALS8 34/4885LGALS4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.